

DREADD

Designer Receptors Exclusively Activated by Designer Drugs (DREADD) are G protein-coupled receptors (GPCRs) that are engineered to be specifically activated by otherwise physiologically inert, drug-like small molecules. They can be used remotely and non-invasively to control cellular signaling, enabling the investigation of relationships between particular cells and their corresponding behaviors. These receptors are generally unresponsive to endogenous ligands, which allows for discrete control of cellular activity with limited off-target effects.




Figure 1. Activation of second-messenger cascades by G protein- and β -arrestin-linked DREADDs.

hM1Dq

Originating Receptor	Ligand(s) Available from Cayman		Signal Transducer	Second Messenger Effect	Downstream Effect
	Item No.	Product Name			
human M ₁ muscarinic	16882	Clozapine N-oxide	G _{oq}	increase Ca ²⁺	neuronal burst firing; smooth muscle contraction

hM3Dq

Originating Receptor	Ligand(s) Available from Cayman		Signal Transducer	Second Messenger Effect	Downstream Effect
	Item No.	Product Name			
human M ₃ muscarinic	16882	Clozapine N-oxide	G _{oq}	increase Ca ²⁺	neuronal burst firing; smooth muscle contraction
	18907	DREADD Agonist 21			
	17756	Perlapine			

hM5Dq

Originating Receptor	Ligand(s) Available from Cayman		Signal Transducer	Second Messenger Effect	Downstream Effect
	Item No.	Product Name			
human M ₅ muscarinic	16882	Clozapine N-oxide	G _{oq}	increase Ca ²⁺	neuronal burst firing; smooth muscle contraction

GsD

Originating Receptor	Ligand(s) Available from Cayman		Signal Transducer	Second Messenger Effect	Downstream Effect
	Item No.	Product Name			
chimeric rat M ₃ muscarinic – turkey β ₁ -adrenergic	16882	Clozapine N-oxide	G _{os}	increase cAMP	modulates plasticity; smooth muscle relaxation

hM2Di

Originating Receptor	Ligand(s) Available from Cayman		Signal Transducer	Second Messenger Effect	Downstream Effect
	Item No.	Product Name			
human M ₂ muscarinic	16882	Clozapine N-oxide	G _{ai}	decrease cAMP; activate β/γ-GIRK	presynaptic inhibition; smooth muscle contraction
	18907	DREADD Agonist 21			
	17756	Perlapine			

hM4Di

Originating Receptor	Ligand(s) Available from Cayman		Signal Transducer	Second Messenger Effect	Downstream Effect
	Item No.	Product Name			
human M ₄ muscarinic	16882	Clozapine N-oxide	G _{ai}	decrease cAMP; activate β/γ-GIRK	presynaptic inhibition; smooth muscle contraction
	18907	DREADD Agonist 21			
	17756	Perlapine			

KORD

Originating Receptor	Ligand(s) Available from Cayman		Signal Transducer	Second Messenger Effect	Downstream Effect
	Item No.	Product Name			
human κ-opioid	23582	Salvinorin B	G _{ai}	decrease cAMP; activate β/γ-GIRK	presynaptic inhibition; smooth muscle contraction
	22244	Salvinorin B Mesylate			

Rq(R165L) or rM3Darr

Originating Receptor	Ligand(s) Available from Cayman		Signal Transducer	Second Messenger Effect	Downstream Effect
	Item No.	Product Name			
rat M ₃ muscarinic	16882	Clozapine N-oxide	β-arrestin	increase arrestin translocation	GPCR desensitization; non-canonical GPCR signaling

Next Generation Designer Ligands for DREADD

Do you need a custom-designed ligand or special formulation for an existing ligand? We can make it for you! Cayman Contract Services has a highly qualified group of medicinal chemists capable of helping to develop the next generation of DREADD ligands.

Learn more at www.caymanchem.com/services